Page 48 - Management of Advanced Urothelial Carcinoma: Emerging Therapies and Biomarkers
P. 48
An expanding treatment landscape
First-line Studies Maintenance Studies
IMVIGOR-130 DANUBE Javelin PREMIER
Objective Atezolizumab mono vs Durvalumab mono vs Avelumab vs Premetrexed
Atezolizumab+chemo Durvalumab +chemo Avelumab+ BSC
Primary INV-assessed PFS, OS PFS (RECIST1.1) OS PFS
endpoint
Secondary
endpoint INV-ORR and DOR OS, ORR, PFS2,HQoL PFS, OR, QoL ORR, OS, QoL
No. patients 1200 1200 668 74
Results July 2020 September 2019 July 2020 June 2020
expected
66 Urothelial Carcinoma Phase 3 and 4 clinical trials*
Chemotherapies and Immunotherapies are the most frequent MOA with other emerging MOAs
under clinical investigation
BSC: Best Supportive Care; MOA: Mode of Action
* https://clinicaltrials.gov; accessed December 12, 2019
